Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001104659-25-059474
Filing Date
2025-06-13
Accepted
2025-06-13 17:21:09
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 20864
2 EXHIBIT 99.1 tm2518013d1_ex99-1.htm EX-99.1 1006
3 GRAPHIC image_001.jpg GRAPHIC 13057
  Complete submission text file 0001104659-25-059474.txt   41882
Mailing Address 860 WASHINGTON STREET 3RD FLOOR NEW YORK NY 10014
Business Address 860 WASHINGTON STREET 3RD FLOOR NEW YORK NY 10014 2123395600
BAKER BROS. ADVISORS LP (Filed by) CIK: 0001263508 (see all company filings)

EIN.: 134093645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A

Mailing Address 175 INNOVATION BOULEVARD WILMINGTON DE 19805
Business Address 175 INNOVATION BOULEVARD WILMINGTON DE 19805 (302) 467-1280
Prelude Therapeutics Inc (Subject) CIK: 0001678660 (see all company filings)

EIN.: 811384762 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-91717 | Film No.: 251047734
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)